Targeting tyrosinase in hyperpigmentation: Current status, limitations and future promises.

Area of Science:

• Dermatology and Cosmetic Science
• Biochemistry and Molecular Biology

Background:

• Hyperpigmentation is a prevalent dermatologic concern.
• Tyrosinase (TYR) is a key enzyme in melanogenesis, making its inhibition a primary therapeutic target.
• Hydroquinone is a traditional but side-effect-prone agent for hyperpigmentation.

Purpose of the Study:

• To review current strategies for hyperpigmentation management, emphasizing TYR inhibition.
• To discuss alternatives to hydroquinone for treating skin pigmentation disorders.
• To explore the potential of nanomedicine and nanotheranostics in hyperpigmentation treatment.

Main Methods:

• Literature review of existing and emerging treatments for hyperpigmentation.
• Focus on tyrosinase inhibitors and their mechanisms.
• Analysis of non-hydroquinone agents and nanomedical approaches.

Main Results:

• Several non-hydroquinone TYR inhibitors have been developed as safer alternatives.
• Nanomedicine offers promising platforms to enhance drug delivery and efficacy for skin disorders.
• Nanotheranostic systems are emerging for improved hyperpigmentation management.

Conclusions:

• Targeting tyrosinase remains a crucial strategy for hyperpigmentation treatment.
• Development of novel non-hydroquinone agents and advanced nanomedical solutions is essential.
• Nanotechnology holds significant potential for optimizing hyperpigmentation therapies.